Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham Research Laboratories, Queen Elizabeth Hospital, University of Birmingham, Birmingham, B15 2WB, UK.
Janssen Pharmaceuticals, Titusville, NJ, USA.
Arthritis Res Ther. 2022 Feb 22;24(1):55. doi: 10.1186/s13075-021-02707-4.
Treatments used for rheumatoid arthritis (RA) are under investigation for their efficacy to prevent RA in at risk groups. It is therefore important to understand treatment preferences of those at risk. We systematically reviewed quantitative preference studies of drugs to treat, or prevent RA, to inform the design of further studies and trials of RA prevention. Stated preference studies for RA treatment or prevention were identified through a search of five databases. Study characteristics and results were extracted, and the relative importance of different types of treatment attributes was compared across populations. Twenty three studies were included 20 of RA treatments (18 of patients; 2 of the general public) and 3 prevention studies with first-degree relatives (FDRs). Benefits, risks, administration method and cost (when included) were important determinants of treatment choice. A benefit was more important than a risk attribute in half of the studies of RA treatment that included a benefit attribute and 2/3 studies of RA prevention. There was variability in the relative importance of attributes across the few prevention studies. In studies with non-patient participants, attributes describing confidence in treatment effectiveness/safety were more important determinants of choice than in studies with patients. Most preference studies relating to RA are of treatments for established RA. Few studies examine preferences for treatments to prevent RA. Given intense research focus on RA prevention, additional preference studies in this context are needed. Variation in treatment preferences across different populations is not well understood and direct comparisons are needed.
用于治疗类风湿关节炎 (RA) 的方法正在研究其在高危人群中预防 RA 的功效。因此，了解高危人群的治疗偏好非常重要。我们系统地综述了治疗或预防 RA 的药物的定量偏好研究，以为 RA 预防的进一步研究和试验提供信息。通过对五个数据库的搜索，确定了 RA 治疗或预防的陈述偏好研究。提取了研究特征和结果，并比较了不同类型的治疗属性在不同人群中的相对重要性。共纳入 23 项研究，其中 20 项为 RA 治疗（18 项为患者，2 项为普通人群），3 项为一级亲属（FDR）的预防研究。获益、风险、给药方法和成本（如果包含）是治疗选择的重要决定因素。在纳入获益属性的半数 RA 治疗研究和 2/3 的 RA 预防研究中，获益比风险属性更重要。在为数不多的预防研究中，属性的相对重要性存在差异。在非患者参与者的研究中，描述对治疗有效性/安全性信心的属性比在患者参与者的研究中更能决定选择。大多数与 RA 相关的偏好研究都是针对已确立的 RA 治疗方法。很少有研究探讨预防 RA 的治疗方法的偏好。鉴于对 RA 预防的研究重点，需要在这方面进行更多的偏好研究。不同人群之间的治疗偏好存在差异，但尚未得到很好的理解，需要进行直接比较。
